Skip to main content

Table 3 Characteristics of included prostate cancer patients with biochemical recurrence

From: Comparison of 18F-sodium fluoride PET/CT, 18F-fluorocholine PET/CT and diffusion-weighted MRI for the detection of bone metastases in recurrent prostate cancer: a cost-effectiveness analysis in France

ParameterAll patientsPatients without bone metastases
(m0BCR)
Patients with bone metastases
(m1BCR)
n55487
Median age in years [range]
 At prostate cancer diagnosis65 [46–78]65 [46–78]66 [55–76]
 At first biochemical recurrence71 [50–87]71 [50–86]72 [56–87]
Initial group according to d’Amico classification
 Low risk7 (13%)70
 Intermediate risk23 (42%)203
 High risk19 (35%)154
 Unknown6 (10%)60
Initial Gleason score
  ≤ 613 (24%)130
 730 (55%)255
  ≥ 88 (15%)80
 Unknown4 (6%)22
Initial International Society of Urological Pathologists (ISUP) 2014 grade group
 113 (24%)130
 217 (30%)134
 310 (18%)100
 47 (13%)70
 51 (2%)10
 Unknown7 (13%)43
First line treatment
 Surgery (prostatectomy ± lymph node dissection)29 (53%)281
 Definitive radiation therapy ± ADT19 (35%)145
 Other local treatment options*7 (12%)61
Median time to biochemical recurrence in months [range]89 [4–228]92 [4–228]87 [6–149]
Median PSA serum value at BCR imaging workup ng/ml [range]4.7 [0.2–137]4.1 [0.2–52]16.5 [1.0–137]
Management of biochemical recurrence after imaging workup
 Salvage radiation therapy (prostatic lodge ± pelvic lymph nodes) ± ADT8 (15%)80
 ADT27 (49%)225
 Surveillance9 (16%)90
 Other treatment option**11 (20%)92
  1. ADT androgen deprivation therapy; *: 4 brachytherapy and 3 high-intensity focused ultrasound (HIFU); **: 1 pelvic lymph node dissection, 7 HIFU, 1 cryoablation, 1 radiation therapy of an isolated bone metastasis and 1 surgery of 2 lung metastasis